B
20B
vs
EXAS
EXAS
Over the past 12 months, 20B has underperformed EXAS, delivering a return of +150% compared to the EXAS's +4 029% growth.
Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
Smart Verdict
AI-Powered
Let AI Decide.
EXAS
Valuation Comparison
| Company | Last Price | Intrinsic Value | DCF Value | Multiples-Based Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
B
|
BioMark Diagnostics Inc
SWB:20B
|
0.35
EUR
|
|||||
|
Exact Sciences Corp
NASDAQ:EXAS
|
1 827.08
USD
|
|||||
Compare the stock's valuation with its competitors.
Growth Comparison
Growth Over Time
20B, EXAS
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
B
|
BioMark Diagnostics Inc
Revenue
|
|||||||||||
|
Exact Sciences Corp
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
20B, EXAS
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
B
|
BioMark Diagnostics Inc
SWB:20B
|
|||||||||
|
Exact Sciences Corp
NASDAQ:EXAS
|
|||||||||
Compare company's free cash flow with its competitors.
Gross Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
B
|
BioMark Diagnostics Inc | ||||
|
Exact Sciences Corp | ||||
Operating Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
B
|
BioMark Diagnostics Inc | ||||
|
Exact Sciences Corp | ||||
Net Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
B
|
BioMark Diagnostics Inc | ||||
|
Exact Sciences Corp | ||||
FCF Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
B
|
BioMark Diagnostics Inc | ||||
|
Exact Sciences Corp | ||||
ROCE
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
B
|
BioMark Diagnostics Inc | ||||
|
Exact Sciences Corp | ||||
Solvency Comparison
Compare company's equity waterfall with its competitors.
Stocks Performance
Stocks Performance
20B, EXAS
Performance By Year
20B, EXAS
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
| US |
|
Natera Inc
NASDAQ:NTRA
|
|
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
|
| FR |
|
Biomerieux SA
PAR:BIM
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
|
| US |
C
|
Caris Life Sciences Inc
NASDAQ:CAI
|
|
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
|
| CH |
|
Siegfried Holding AG
SIX:SFZN
|
|
| IT |
|
DiaSorin SpA
MIL:DIA
|
|
| UK |
|
Abcam PLC
LSE:ABC
|